These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 6420517)
1. DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness. Birkmayer W; Birkmayer G; Lechner H; Riederer P J Neural Transm; 1983; 58(3-4):305-13. PubMed ID: 6420517 [TBL] [Abstract][Full Text] [Related]
2. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Mathias CJ; Senard JM; Braune S; Watson L; Aragishi A; Keeling JE; Taylor MD Clin Auton Res; 2001 Aug; 11(4):235-42. PubMed ID: 11710796 [TBL] [Abstract][Full Text] [Related]
3. Improvement in freezing phenomenon of Parkinson's disease after DL-threo-3, 4-dihydroxyphenylserine. Ogawa N; Kuroda H; Yamamoto M; Nukina I; Ota Z Acta Med Okayama; 1984 Jun; 38(3):301-4. PubMed ID: 6431755 [TBL] [Abstract][Full Text] [Related]
4. Treatment of orthostatic hypotension in Shy-Drager syndrome with DL-threo-3,4-dihydroxyphenylserine: a case report. Sakoda S; Suzuki T; Higa S; Ueji M; Kishimoto S; Matsumoto M; Yoneda S Eur Neurol; 1985; 24(5):330-4. PubMed ID: 3932074 [TBL] [Abstract][Full Text] [Related]
5. Effect of L-threo-3,4-dihydroxyphenylserine chronic administration on cerebrospinal fluid and plasma free 3-methoxy-4-hydroxy-phenylglycol concentration in patients with Parkinson's disease. Yamamoto M; Ogawa N; Ujike H J Neurol Sci; 1986 Mar; 73(1):39-44. PubMed ID: 3084714 [TBL] [Abstract][Full Text] [Related]
6. The effects of the noradrenaline precursor, L-threo-3,4-dihydroxyphenylserine, in children with orthostatic intolerance. Tanaka H; Yamaguchi H; Mino M Clin Auton Res; 1996 Aug; 6(4):189-93. PubMed ID: 8902314 [TBL] [Abstract][Full Text] [Related]
7. DL-Threo-3,4-dihydroxyphenylserine does not exert a pressor effect in orthostatic hypotension. Hoeldtke RD; Cilmi KM; Mattis-Graves K Clin Pharmacol Ther; 1984 Sep; 36(3):302-6. PubMed ID: 6432398 [TBL] [Abstract][Full Text] [Related]
8. d,l-threo-3,4-dihydroxyphenylserine restores sympathetic control and cures orthostatic hypotension in dopamine beta-hydroxylase deficiency. Man in 't Veld AJ; Boomsma F; van den Meiracker AH; Julien C; Lenders J; Schalekamp MA J Hypertens Suppl; 1988 Dec; 6(4):S547-9. PubMed ID: 3149290 [TBL] [Abstract][Full Text] [Related]
9. Substantial renal conversion of L-threo-3,4-dihydroxyphenylserine (droxidopa) to norepinephrine in patients with neurogenic orthostatic hypotension. Lamotte G; Holmes C; Sullivan P; Goldstein DS Clin Auton Res; 2019 Feb; 29(1):113-117. PubMed ID: 30229336 [TBL] [Abstract][Full Text] [Related]
10. Treatment of parkinsonism with L-threo-3,4-dihydroxyphenylserine: a pharmacokinetic study. Suzuki T; Sakoda S; Ueji M; Kishimoto S; Hayashi A; Kondo T; Narabayashi H Neurology; 1984 Nov; 34(11):1446-50. PubMed ID: 6436731 [TBL] [Abstract][Full Text] [Related]
14. Improved orthostatic tolerance in familial amyloidotic polyneuropathy with unnatural noradrenaline precursor L-threo-3,4-dihydroxyphenylserine. Carvalho MJ; van den Meiracker AH; Boomsma F; Man in 't Veld AJ; Freitas J; Costa O; de Freitas AF J Auton Nerv Syst; 1997 Jan; 62(1-2):63-71. PubMed ID: 9021651 [TBL] [Abstract][Full Text] [Related]
15. Effect of long-term L-threo-3,4-dihydroxyphenylserine administration on alpha 2-adrenergic receptors in platelet membranes in neurologic disorders. Azuma T; Suzuki T; Sakoda S; Mizuno R; Tsujino S; Kobayashi T; Kishimoto S; Hiraga T; Matsubara T; Yoshida S Acta Neurol Scand; 1991 Jul; 84(1):46-50. PubMed ID: 1656690 [TBL] [Abstract][Full Text] [Related]
16. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial. Freeman R; Landsberg L; Young J Neurology; 1999 Dec; 53(9):2151-7. PubMed ID: 10599797 [TBL] [Abstract][Full Text] [Related]
17. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A). Hauser RA; Hewitt LA; Isaacson S J Parkinsons Dis; 2014; 4(1):57-65. PubMed ID: 24326693 [TBL] [Abstract][Full Text] [Related]
18. Mass spectrometric measurements of norepinephrine synthesis in man from infusion of stable isotope-labelled L-threo-3,4-dihydroxyphenylserine. Suzuki T; Sakoda S; Ueji M; Kishimoto S Life Sci; 1985 Feb; 36(5):435-42. PubMed ID: 3918223 [TBL] [Abstract][Full Text] [Related]
19. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B). Hauser RA; Isaacson S; Lisk JP; Hewitt LA; Rowse G Mov Disord; 2015 Apr; 30(5):646-54. PubMed ID: 25487613 [TBL] [Abstract][Full Text] [Related]
20. Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension. Gupta F; Karabin B; Mehdirad A Clin Auton Res; 2017 Jul; 27(Suppl 1):15-16. PubMed ID: 28699047 [No Abstract] [Full Text] [Related] [Next] [New Search]